Loading...
Prezentacije/ Članci
Loading...
| ARTICLE | |
 Angioplastyka wieńcowa oraz wymiana zastawki aortalnej u dwóch chorych ze szpiczakiem mnogim – opisy przypadków »Coronary angioplasty and aortic valve replacement in two patients with multiple myeloma – case reports dr n. med. Artur Jurczyszyn, lek. Maria Mrozek, lek. Joanna Paleń, dr hab. n. med. Marek Rajzer, dr n. med. Michał Terlecki, prof. dr hab. n. med. Aleksander B. Skotnicki - © 2012 OncoReview |  PDF - 434 kB |
| Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p » Kai Neben, Henk M. Lokhorst, Anna Jauch, Uta Bertsch, Thomas Hielscher, Bronno van der Holt, Hans Salwender, Igor W. Blau, Katja Weisel, Michael Pfreundschuh, Christof Scheid, Ulrich Du¨hrsen, Walter Lindemann, Ingo G. H. Schmidt-Wolf, Norma Peter, Christian Teschendorf, Hans Martin, Mathias Haenel, Hans G. Derigs, Marc S. Raab, Anthony D. Ho, Helgi van de Velde, Dirk Hose, Pieter Sonneveld and Hartmut Goldschmidt - © 2012 by The American Society of Hematology. Blood | PDF - 525 kB |
| Epidemiology of the plasma-cell disorders » Robert A. Kyle MD, S. Vincent Rajkumar MD - © Best Practice & Research Clinical Haematology Vol. 20, No. 4, pp. 637–664 | PDF - 707 kB |
| Aphase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma » Andrzej J. Jakubowiak, Dominik Dytfeld, Kent A. Griffith, Daniel Lebovic, David H. Vesole, Sundar Jagannath, Ammar Al-Zoubi, Tara Anderson, Brian Nordgren, Kristen Detweiler-Short, Keith Stockerl-Goldstein, Asra Ahmed, Terri Jobkar, Diane E. Durecki, Kathryn McDonnell, Melissa Mietzel, Daniel Couriel, Mark Kaminski and Ravi Vij - © UNIVERSITY OF CHICAGO LIBRARY on November 28, 2012 | PDF - 357 kB |
| Rare Manifestations of Multiple Myeloma » Artur Jurczyszyn - © 2012 Jurczyszyn licensee InTech. | PDF - 268 kB |
| International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma Related Bone Disease » Evangelos Terpos, Gareth Morgan, Meletios A. Dimopoulos, Noopur Raje, Niels Abildgaard, Matthew Drake, Ramón García-Sanz, Kazuyuki Shimizu, Faith Davies, Ingemar Turesson, Jae Hoon Lee, Artur Jurczyszyn, Giampaolo Merlini, Paul Richardson, Michele Cavo, Nikhil Munsi, Brian G.M. Durie, Vincent Rajkumar, G. David Roodman - © 2012 | PDF - 165 kB |
| Novel Therapies for Relapsed/Refractory Multiple Myeloma: How Can We Improve on “Salvage” Therapy?—Introduction » Andrzej Jakubowiak, MD, PhD - © Seminars in Hematology, Vol 49, No 3, Suppl 1, July 2012 Relapsed/Refractory Multiple Myeloma: Defining Refractory Disease and Identifying Strategies to Overcome Resistance »David S. Siegel - © Seminars in Hematology, Vol 49, No 3, Suppl 1, July 2012 Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives »Andrzej Jakubowiak - © Seminars in Hematology, Vol 49, No 3, Suppl 1, July 2012 The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies »Philippe Moreau - © Seminars in Hematology, Vol 49, No 3, Suppl 1, July 2012 | PDF - 641 kB |
| Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma » Antonio Palumbo, M.D., Roman Hajek, M.D., Ph.D., Michel Delforge, M.D., Ph.D., Martin Kropff, M.D., Maria Teresa Petrucci, M.D., John Catalano, M.B., B.S., Heinz Gisslinger, M.D., Wiesław Wiktor-Jędrzejczak, M.D., Ph.D., Mamia Zodelava, M.D., Ph.D., Katja Weisel, M.D., Nicola Cascavilla, M.D., Genadi Iosava, M.D., Michele Cavo, M.D., Janusz Kloczko, M.D., Ph.D., Joan Bladé, M.D., Meral Beksac, M.D., Ivan Spicka, M.D., Ph.D., Torben Plesner, M.D., Joergen Radke, M.D., Christian Langer, M.D., Dina Ben Yehuda, M.D., Alessandro Corso, M.D., Lindsay Herbein, B.S., Zhinuan Yu, Ph.D., Jay Mei, M.D., Ph.D., Christian Jacques, M.D., and Meletios A. Dimopoulos, M.D., for the MM-015 Investigators - © 2012 Massachusetts Medical Society, The New England Journal of Medicine | PDF - 886 kB |
| Leki immunomodulujące w leczeniu pierwotnej układowej amyloidozy łańcuchów lekkich » Grzegorz Charllński, Elżbieta Wiater, Wiesław Wiktor Jędrzejczak - © 2012 Warszawski Uniwersytet Medyczny, Katedra i Klinika Hematologii, Onkologii i Chorób Wewnętrznych | PDF - 103 kB |
| European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses » Heinz Ludwig, Herve Avet-Loiseau, Joan Blade, Mario Boccadoro, Jamie Cavenagh, Michele Cavo, Faith Davies, Javier De La Rubia, Sosana Delimpasi, Meletios Dimopoulos, Johannes Drach, Hermann Einsele, Thierry Facon, Hartmut Goldschmidt, Urs Hess, Ulf-Henrik Mellqvist, Philippe Moreau, Jesus San-Miguel, Pia Sondergeld, Pieter Sonneveld, Miklos Udvardy, Antonio Palumbo - © The Oncologist 2012 | PDF - 1,16 MB |
| An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification » Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, Tian E, Williams DR, Epstein J, Barlogie B, Shaughnessy JD Jr. - © Blood. 2012 Jan 12;119(2):503-12. Epub 2011 Nov 9. |  HTML |
| Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity » Sato N, Hattori Y, Wenlin D, Yamada T, Kamata T, Kakimoto T, Okamoto S, Kawamura C, Kizaki M, Shimada N, Ote Y, Hata J, Ikeda Y. - © Jpn J Cancer Res. 2002 Apr;93(4):459-66. | HTML |
| A Review of the Cytokine Network in Multiple Myeloma - Diagnostic, Prognostic, and Therapeutic Implications » Vito Michele Lauta, M.D. - © 2003 American Cancer Society | PDF - 196 kB |
| Elevated Serum Concentration of Hepatocyte Growth Factor in Patients With Multiple Myeloma: Correlation With Markers of Disease Activity » M.G. Alexandrakis, F.H. Passarn, A. Sfiridaki, E. Kandidaki, P. Roussou and 0.S. Kyriakou - © 2003 Wiley-Liss, Inc. / American Journal of Hematology 72:229-233 (2003) | PDF - 121 kB |
| Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide » Jose Mario Meriz and Graca Vasconcelos Esteves - © 2012 Wolters Kluwer Health / Lippincott Williams & Wilkins | PDF - 210 kB |
| Medical Progress Multiple Myeloma » Antonio Palumbo M.D., Kenneth Anderson M.D. - © 2011 Massachusetts Medical Society | PDF - 886 kB |
| Continuing medical education activity in American Journal of Hematology » CME Editor: Ayalew Tefferi, MD; Author: Morie Gertz, MD - © 2012 Wiley Periodicals, Inc.; American Journal of Hematology | PDF - 794 kB |
| Medical Progress Multiple Myeloma » Antonio Palumbo, M.D., and Kenneth Anderson, M.D. - The New England Journal of Medicine, March 17, 2011 | PDF - 886 kB |
| Gain(1)(q21) is an unfavorable genetic prognostic factor for relapsed multiple myeloma patients treated with thalidomide, but not for those treated with bortezomib. » Smetana, J, Berankova, K, Zaoralova, R, Nemec, P, Greslikova, H, Zahradová, L, Krejci, M, Almasi, M, Sandecka, V, Adam, Z, Penka, M, Jurczyszyn A, Hájek, R, Kuglík, P | PDF - 186 kB |
| Leczenie chorych na szpiczaka mnogiego poniżej 65.–70. roku życia oraz rola terapii podtrzymującej po przeszczepieniu komórek macierzystych » Treatment of patients with multiple myeloma than 65–70 years of age and the role of maintenance therapy after transplantation stem cells Dr n. med. Artur Jurczyszyn - Onco Review 2011 | PDF - 323 kB |
| Multiple Myeloma CCO Independent Conference Highlights of the 2012 American Society of Clinical Oncology Annual Meeting » Sagar Lonial, Robert Z. Orlowski - © June 1-5, 2012 Chicago, Illinois | PDF - 337 kB |
| Management of Multiple Myeloma » Kenneth Anderson 2011 | PDF - 205 kB |
| Rola badań cytogenetycznych w indywidualizacji leczenia szpiczaka mnogiego » The role of cytogenetics in individualization of multiple myeloma treatment Dominik Dytfeld, Barbara Pieńkowska, Jan Maciej Zaucha - Acta Haematologica Polonica 2011, 42, Nr 3, str. 473–482 | PDF - 138 kB |
| Terapia nawrotowego i opornego szpiczaka plazmocytowego » Therapy of relapsed and refractory plasma cell myeloma Krzysztof Jamroziak, Klinika Hematologii, Uniwersytet Medyczny w Łodzi - Hematologia 2011, tom 2, nr 1, 116–130 | PDF - 117 kB |
| Can multiple myeloma become a curable disease? » Jesús F. San-Miguel and María-Victoria Mateos - Servicio de Hematología, Hospital Universitario de Salamanca, CIC, IBMCC (USAL-CSIC), Salamanca, Spain | PDF - 95 kB |
| Wpływ czasu trwania terapii lenalidomidem z deksametazonem na przeżywalność pacjentów z nawrotowym lub opornym na leczenie szpiczakiem mnogim leczonych lenalidomidem z deksametazonem » Jesús F. San-Miguel, Meletios A. Dimopoulos, Edward A. Stadtmauer, S. Vincent Rajkumar, David Siegel, Marie-Laure Bravo, Marta Olesnyckyj, Robert D. Knight, Jerome B. Zeldis, Jean-Luc Harousseau, Donna M. Weber - Clinical Lymphoma, Myeloma & Leukemia, grudzień 2010 | PDF - 771 kB |
| International Myeloma Working Group Consensus Statement - Second Primary Cancers » January 30-31, 2011 Santa Monica, CA | PDF - 344 kB |
| The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma—A report by the Polish Myeloma Study Group » Anna Dmoszynska, Adam Walter-Croneck, Iwona Hus, Norbert Grzasko, Joanna Manko, Wieslaw Wiktor Jedrzejczak, Grzegorz Charlinski, Lidia Usnarska-Zubkiewicz, Aleksander Skotnicki, Teresa Wolska-Smolen, Jaroslaw Piszcz, Janusz Kloczko - Leukemia Research 34 (2010) 1330–1335 | PDF - 297 kB |
| Proteasomy – nowy cel leczenia przeciwnowotworowego » Proteasomes – a new target for anticancer therapy Agnieszka Kostur, Agnieszka Kulczyńska, Janusz Kłoczko - Acta Haematologica Polonica 2010, 41, Nr 2, str. 261–269 | PDF - 306 kB |
| Freelite ™ Serum Free Light Chain Assays » (Recommended by International Myeloma Working Group guidelines for B cell Dyscrasias) - The Binding Site | PDF - 2,07 MB |
| International Myeloma Working Group guidelines for serum free light chain analysis in multiple myeloma and related disorders » INVITED MANUSCRIPT: Leukemia Spotlight Series | PDF - 353 kB |
| The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement » Leukemia (2008), 1–6 & 2008 Nature Publishing Group | PDF - 124 kB |
| Part of the IMF Patient Education Tools Series » Reprint • June 2008 • Supplement to Volume 12, Number 3 • Clinical Journal of Oncology Nursing | PDF - 730 kB |
| Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group » BLOOD, 15 APRIL 2008 - VOLUME 111, NUMBER 8 | PDF - 831 kB |
| Thromboembolic Events - Associated With Novel Therapies in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board » June 2008 • Supplement to Volume 12, Number 3 • Clinical Journal of Oncology Nursing | PDF - 214 kB |
| Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma » Leukemia (2008) 22, 414–423 & 2008 Nature Publishing Group | PDF - 180 kB |
| Steroid-Associated Side Effects in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board » June 2008 • Supplement to Volume 12, Number 3 • Clinical Journal of Oncology Nursing | PDF - 238 kB |
| Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma » haematologica | 2008; 93(5) | PDF - 173 kB |
| Peripheral Neuropathy - Associated With Novel Therapies in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board » June 2008 • Supplement to Volume 12, Number 3 • Clinical Journal of Oncology Nursing | PDF - 209 kB |
| Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement » MAYO CLIN PROC. 2007;82:516-522 © 2007 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | PDF - 37 kB |
| Myelosuppression - Associated With Novel Therapies in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board » June 2008 • Supplement to Volume 12, Number 3 • Clinical Journal of Oncology Nursing | PDF - 189 kB |
| International uniform response criteria for multiple myeloma » Leukemia (2006), 1–7 & 2006 Nature Publishing Group | PDF - 116 kB |
| Gastrointestinal Side Effects - Associated With Novel Therapies in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board » June 2008 • Supplement to Volume 12, Number 3 • Clinical Journal of Oncology Nursing | PDF - 256 kB |
| International Staging System for Multiple Myeloma » Downloaded from www.jco.org at CEDARS SINAI MEDICAL CENTER MEDICAL LIBRARY on April 4, 2005 | PDF - 697 kB |
| Management of Side Effects of Novel Therapies for Multiple Myeloma: Consensus Statements Developed by the International Myeloma Foundation’s Nurse Leadership Board » June 2008 • Supplement to Volume 12, Number 3 • Clinical Journal of Oncology Nursing | PDF - 112 kB |
| Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation » The Hematology Journal (2003) 4, 379-398 | PDF - 2,04 MB |
| Oncology Nurses Take the Lead in Providing Novel Therapy Guidelines for Multiple Myeloma » Brian G.M. Durie, MD—International Myeloma Foundation - June 2008 • Supplement to Volume 12, Number 3 • Clinical Journal of Oncology Nursing | PDF - 74 kB |
| Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group » British Journal of Haematology, 2003, 121, 749–757 | PDF - 93 kB |
| Zmiany na błonie śluzowej jamy ustnej w przebiegu choroby ogólnoustrojowej – na co należyzwrócić uwagę? Osteonekroza kości szczęk oraz zmiany na błonie śluzowej jamy ustnej u chorych ze szpiczakiem mnogim lub amyloidozą » dr n. med. Maciej R. Czerniuk, Agata Gieorgijewska, dr n. med. Artur Jurczyszyn - "Kardiologia po Dyplomie" (maj 2010) 9(5); 65-70 | PDF - 208 kB |
| Profilaktyka i leczenie działań niepożądanych lenalidomidu » Dr med. Wojciech Legieć – Klinika Hematoonkologii i Transplantacji Szpiku – Lublin | PDF - 564 kB |
| Resweratrol - od wina do szpiczaka » Prof. dr hab. Zbigniew Janeczko | PDF - 659 kB |
| Właściwości biologiczne resweratrolu i możliwości jego stosowania w terapii szpiczaka mnogiego » Prof. dr hab. Zbigniew Janeczko, dr n. med. Artur Jurczyszyn, mgr farm. Barbara Bochenek - "Panacea" kwiecień-czerwiec 2009 | PDF - 500 kB |
| Polineuropatia wywołana talidomidem i bortezomibem u chorych na szpiczaka mnogiego, możliwości leczenia bólu neuropatycznego. Zalecenia Polskiej Grupy Szpiczakowej » Thalidomide and bortezomib induced neuropathy in multiple myeloma, possibility of treatment of neuropathic pain. Recommendations of the Polish Myeloma Study Group Małgorzata Bilińska, Lidia Usnarska-Zubkiewicz, Anna Dmoszyńska - "Współczesna Onkologia" (2008) 12; 10 (441-446) | PDF - 80 kB |
| Znaczenie badań obrazowych w diagnostyce szpiczaka » dr n. med. Artur Jurczyszyn - Klinika Hematologii Szpital Uniwersytecki, 31-501 Kraków, ul. Kopernika 17, tel. 601 539077; e-mail: mmjurczy@cyf-kr.edu.pl; redakcja - prof. Anna Dmoszyńska | PDF - 241 kB |
| Historia odkrycia szpiczaka mnogiego » dr n. med. Artur Jurczyszyn, prof. dr hab. med. Aleksander B. Skotnicki - Klinika Hematologii Szpitala Uniwersyteckiego w Krakowie; redakcja - prof. Anna Dmoszyńska | PDF - 189 kB |
| Terapia szpiczaka mnogiego » dr n. med. Artur Jurczyszyn - "Służba Zdrowia" nr.13-17/2009 (3814-3818) z 23 lutego 2009 | PDF - 112 kB |
| Aktualne miejsce bortezomibu w leczeniu szpiczaka mnogiego » Current appliance of bortezomib in multiple myeloma treatment dr n. med. Halina Urbańska-Ryś, dr n. med. Monika Ryś - "Współczesna Onkologia" (2008) vol. 12; 9 (415-420) | PDF - 81 kB |
| Treatment of Myeloma: Cure vs Control » S. Vincent Rajkumar, MD - Mayo Clin Proceedings, October 2008;83(10):1142-1145 | PDF - 48 kB |
| Advances in the Frontline Treatment of Multiple Myeloma » Professor of Medicine Amitabha Mazumder, MD - Clinical Care Options Oncology | PDF - 287 kB |
| A review of lenalidomide in combination with dexamethasone for the treat- ment of multiple myeloma » Teru Hideshima, Noopur Raje, Paul G Richardson, Kenneth C. Anderson - "Therapeutics and Clinical Risk Management 2008" | PDF - 440 kB |
| Current Trends in Multiple Myeloma Management » J. Redzepovic, G. Weinmann, I. Ott, R. Gust - "The Journal of International Medical Research" 2008; 36: 371-386 | PDF - 227 kB |
| Postępy w diagnostyce szpiczaka plazmocytowego » dr n. med. Artur Jurczyszyn | PDF - 1.441 kB |
| Bortezomib - pierwszy inhibitor proteasomów w terapii szpiczaka mnogiego » Bortezomib - first proteasome inhibitor for the treatment of multiple myeloma dr n. med. Artur Jurczyszyn, prof. dr hab. med. Aleksander B. Skotnicki - "Współczesna Onkologia" (2007) vol. 11; 3 (112-124) | PDF - 368 kB |
| Nowe leki w terapii szpiczaka mnogiego » New drugs in the therapy of multiple myeloma dr n. med. Artur Jurczyszyn, prof. dr hab. med. Aleksander B. Skotnicki - "Współczesna Onkologia" (2007) vol. 11; 4 (186-194) | PDF - 184 kB |
| Nowości w leczeniu szpiczaka mnogiego (przypadki kliniczne) » dr n. med. Artur Jurczyszyn | PDF - 596 kB |
| Terapia wspomagająca w szpiczaku mnogim » dr n. med. Artur Jurczyszyn | PDF - 199 kB |
| Nowe metody diagnostyczne w szpiczaku mnogim » dr n. med. Artur Jurczyszyn | PDF - 1.015 kB |
| Nowości w terapii szpiczaka mnogiego: „post-ASH” 2007 » dr n. med. Artur Jurczyszyn | PDF - 1.050 kB |
| Optymalna terapia pacjentów ze szpiczakiem mnogim. Przypadki kliniczne » dr n. med. Artur Jurczyszyn | PDF - 356 kB |
| Cytokiny w patogenezie szpiczaka mnogiego » dr n. med. Artur Jurczyszyn - praca doktorska | PDF - 2.784 kB |
| Szpiczak mnogi - rola angiogenezy i zastosowanie talidomidu » Multiple myeloma - the role of angiogenesis and therapeutic application of thalidomide dr n. med. Artur Jurczyszyn, dr n. med. Teresa Wolska-Smoleń, prof. dr hab. med. Aleksander B. Skotnicki - "Przegląd Lekarski" | PDF - 337 kB |
| Nowotwory ukladów krwiotwórczego i limfoidalnego » Praca zbiorowa - Redakcja: prof. dr hab. med. Wiesław Wiktor Jędrzejczak | PDF - 797 kB |
Odradio: dr n. med. Artur Jurczyszyn
Klinika Hematologije Univerzitetskog Klinickog Centra u Krakovu
31-501 Krakov, ul. Kopernika 17, Poljska
tel. +48 12 424 7426 ili +48 12 424 7633
Tekuci racuni u PLN : 06 1440 1127 0000 0000 0835 9709
